Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients

Clinical Infectious Diseases

Volumn 59, Issue 11, 2014, Pages 1537-1545

  Lúcia, Marc ^a   Crespo, Elena ^a   Melilli, Edoardo ^a   Cruzado, Josep M ^a   Luque, Sergi ^a   Llaudó, Inés ^a   Niubó, Jordi ^a   Torras, Joan ^a   Fernandez, Núria ^a   Grinyó, Josep M ^a   Bestard, Oriol ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Adaptive immunity; CMV infection; Kidney transplantation; T and B cell ELISPOT assay

Indexed keywords

BASILIXIMAB; IMMUNOGLOBULIN G ANTIBODY; THYMOCYTE ANTIBODY; GAMMA INTERFERON;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CASE CONTROL STUDY; CLINICAL STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMORAL IMMUNITY; INFECTION RISK; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VIREMIA; AGED; B LYMPHOCYTE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED; T LYMPHOCYTE;

ADULT; AGED; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 84915799205     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu589     Document Type: Article

References (28)

1. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-6.
2. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329-37.
3. + T-cell immunity to cytomegalovirus. Hum Immunol 2004; 65: 456-64.
4. Polić B, Hengel H, Krmpotić A, et al. Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med 1998; 188: 1047-54.
5. Pahl-Seibert M-F, Juelch M, Podlech J, et al. Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol 2005; 79: 5400-13.
6. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-83.
7. Atabani SF, Smith C, Atkinson C, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457-64.
8. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. NEJM 1999; 340: 1462-70.
9. Lúcia M, Crespo E, Cruzado JM, Grinyó JM, Bestard O. Human CMV-specific T-cell responses in kidney transplantation: towards changing current risk-stratification paradigm. Transpl Int 2014; 27: 643-56.
10. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-22.
11. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56: 817-24.
12. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomega-lovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031-6.
13. Bestard O, Lucia M, Crespo E, et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant 2013; 13: 1793-805.
14. West D. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996; 14: 1019-27.
15. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-7.
16. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-74.
17. Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, Ahlborg N. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J Immunol Methods 2013; 391: 50-9.
18. Shabir S, Kaul B, Pachnio A, et al. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation. J Am Soc Nephrol 2013; 24: 1698-708.
19. Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 2577-84.
20. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195: 633-44.
21. Plotkin SA Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055-65.
22. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272: 54-60.
23. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010; 236: 125-38.
24. McHeyzer-Williams MG, Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999; 11: 172-9.
25. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22: 76-98.
26. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29.
27. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8: 990-9.
28. Sester U, Presser D, Dirks J, Gärtner BC, Köhler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 2008; 8: 1486-97.